Misplaced Pages

This is an old revision of this page, as edited by Bluebot (talk | contribs) at 11:35, 6 November 2005 (Bringing "External links" and "See also" sections in line with Manual of Style recommendations.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission.

Examples of NaSSAs include:

• Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)

NaSSAs are said to have fewer side-effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with NaSSAs.

See also

• Clinical depression

External links

• J. Fawcett, R. L. Barkin: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression

This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Medical treatment stubs
• Antidepressants